Neurodegeneration in multiple sclerosis: novel treatment strategies

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ern.12.59PMID 23039386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo-controlled trial of oral laquinimod for multiple sclerosis.

  2012cited by this paper
• Immune mechanisms of new therapeutic strategies in MS: teriflunomide.

  2012cited by this paper
• Mitochondrial changes within axons in multiple sclerosis: an update.

  2012cited by this paper
• Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.

  2011cited by this paper
• Interleukin‐2/interleukin‐2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation

  2011cited by this paper
• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

  2011cited by this paper
• Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

  2011cited by this paper
• High Resolution Spectral Domain Optical Coherence Tomography (SD-OCT) in Multiple Sclerosis: The First Follow Up Study over Two Years

  2011cited by this paper
• Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study

  2010cited by this paper
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  2010cited by this paper
• In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis.

  2010cited by this paper
• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

  2010cited by this paper
• Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Multiple sclerosis - candidate mechanisms underlying CNS atrophy.

  2010cited by this paper
• Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

  2010cited by this paper
• Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

  2010cited by this paper
• Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

  2010cited by this paper
• HLA-DQ8 (DQB1*0302)-Restricted Th17 Cells Exacerbate Experimental Autoimmune Encephalomyelitis in HLA-DR3-Transgenic Mice 1

  2009cited by this paper
• Green Tea Epigallocatechin 3-Gallate Accumulates in Mitochondria and Displays a Selective Antiapoptotic Effect Against Inducers of Mitochondrial Oxidative Stress in Neurons

  2009cited by this paper
• Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis

  2009cited by this paper
• The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative Stress*

  2009cited by this paper
• Microglial physiology: unique stimuli, specialized responses.

  2009cited by this paper
• Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis.

  2009cited by this paper
• Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

  2009cited by this paper
• Axonal degeneration in multiple sclerosis: The mitochondrial hypothesis

  2009cited by this paper
• Alemtuzumab versus interferon beta-1a in early multiple sclerosis

  2009cited by this paper
• A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes.

  2009cited by this paper
• Cytotoxic CD8+ T Cell–Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death

  2009cited by this paper
• Molecular antagonism and plasticity of regulatory and inflammatory T cell programs.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Multiple sclerosis: an immune or neurodegenerative disorder?

  2008cited by this paper
• Long‐Term Study of Brain 1H‐MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long‐Term 1H‐MRS Monitoring in Multiple Sclerosis

  2008cited by this paper
• Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

  2008cited by this paper
• Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis

  2008cited by this paper
• Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.

  2008cited by this paper
• The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

  2008cited by this paper
• Axon-glial signaling and the glial support of axon function.

  2008cited by this paper
• Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

  2008cited by this paper
• RETINAL NERVE FIBER LAYER IS ASSOCIATED WITH BRAIN ATROPHY IN MULTIPLE SCLEROSIS

  2008cited by this paper
• Mitochondrial defects in acute multiple sclerosis lesions

  2008cited by this paper
• Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo

  2008cited by this paper
• Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

  2008cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

  2008cited by this paper
• Mechanisms of Disease: sodium channels and neuroprotection in multiple sclerosis—current status

  2008influential reference
• Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis

  2007cited by this paper
• Histopathology and serial, multimodal magnetic resonance imaging in a multiple sclerosis variant

  2007cited by this paper
• Interferon- and neuroprotection in multiple sclerosisFacts, hopes and phantasies

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway.

  2007cited by this paper
• Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system

  2007cited by this paper
• MR Spectroscopy in Multiple Sclerosis

  2007cited by this paper
• New natural history of interferon-beta-treated relapsing multiple sclerosis.

  2007cited by this paper
• Microglial recruitment, activation, and proliferation in response to primary demyelination.

  2007cited by this paper
• Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

  2007cited by this paper
• Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine

  2007cited by this paper
• Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.

  2007cited by this paper
• Optical coherence tomography and disease subtype in multiple sclerosis

  2007cited by this paper
• LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

  2007cited by this paper
• Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

  2007cited by this paper
• New natural history of interferon‐β–treated relapsing multiple sclerosis

  2007cited by this paper
• Evidence for synaptic stripping by cortical microglia

  2007cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Brain atrophy in multiple sclerosis: what we know and would like to know

  2006influential reference
• New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis

  2006cited by this paper
• Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients

  2006cited by this paper
• Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions.

  2006cited by this paper
• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

  2006cited by this paper
• Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.

  2006cited by this paper
• Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.

  2006cited by this paper
• Experimental autoimmune encephalomyelitis repressed by microglial paralysis

  2005cited by this paper
• Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo

  2005cited by this paper
• Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis

  2005cited by this paper
• Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.

  2005cited by this paper
• Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.

  2005cited by this paper
• Emerging properties of cannabinoid medicines in management of multiple sclerosis.

  2005cited by this paper
• Cortical demyelination and diffuse white matter injury in multiple sclerosis.

  2005cited by this paper
• Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate.

  2005cited by this paper
• Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

  2005cited by this paper
• Na+-Dependent Sources of Intra-Axonal Ca2+ Release in Rat Optic Nerve during In Vitro Chemical Ischemia

  2005cited by this paper
• Sodium channels contribute to microglia/macrophage activation and function in EAE and MS

  2005cited by this paper
• Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice.

  2005cited by this paper
• Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis

  2004cited by this paper
• Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

  2004cited by this paper
• Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis

  2004cited by this paper
• Patterns of cannabis use among patients with multiple sclerosis

  2004cited by this paper
• Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis.

  2004cited by this paper
• Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1

  2004cited by this paper
• Analysis of regulatory CD8 T cells in Qa-1-deficient mice

  2004cited by this paper
• Axonal protection using flecainide in experimental autoimmune encephalomyelitis

  2004cited by this paper
• Magnetization Transfer Magnetic Resonance Imaging in the Assessment of Neurological Diseases

  2004cited by this paper
• Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

  2004cited by this paper
• New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application.

  2004cited by this paper
• Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue

  2004cited by this paper
• Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.

  2004cited by this paper
• Are statins a treatment option for multiple sclerosis?

  2004cited by this paper
• Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration

  2003cited by this paper
• Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor Vβ repertoire during experimental autoimmune encephalomyelitis

  2003cited by this paper
• The Pleiotropic Effects of Erythropoietin in the Central Nervous System

  2003cited by this paper

• The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistance.

  2023cites this paper
• The effect of probiotics on immune responses and their therapeutic application: A new treatment option for multiple sclerosis.

  2023cites this paper
• 1,2-13C2-Glucose Tracing Approach to Assess Metabolic Alterations of Human Monocytes under Neuroinflammatory Conditions

  2023cites this paper
• The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity

  2023influential citation
• Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis

  2023cites this paper
• Effect of smartphone application-assisted nursing intervention on breastfeeding self-efficacy of postpartum women with multiple sclerosis

  2023cites this paper
• Investigation of Neurodegeneration Investigation of Neurodegeneration

  2022cites this paper
• Dietary patterns and risk of multiple sclerosis: Results of a double-center case-control study in Iran

  2022cites this paper
• Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.

  2021cites this paper
• Oligodendroglial glycolipids in (Re)myelination: implications for multiple sclerosis research.

  2021cites this paper
• Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers

  2021cites this paper
• The Potential Contribution of Dysfunctional RNA-Binding Proteins to the Pathogenesis of Neurodegeneration in Multiple Sclerosis and Relevant Models

  2020cites this paper
• The role of the brain in the treatment of multiple sclerosis as a connectomopathy.

  2020cites this paper
• The role of the brain in the treatment of multiple sclerosis as a connectomopathy.

  2020cites this paper
• Bilateral retinal pathology following a first-ever clinical episode of autoimmune optic neuritis

  2020cites this paper
• The Predictive Role of Neurobiochemical Markers in Multiple Sclerosis

  2020cites this paper
• Use of rituximab in adults with relapsing–remitting multiple sclerosis: a systematic literature review

  2020cites this paper
• Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis

  2020cites this paper
• Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

  2019cites this paper
• Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis

  2019cites this paper
• Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis

  2019cites this paper
• ANTIAPOPTOSIS ACTIVITY OF PLANT POLYPRENYLPHOSPHATE AGAINST MACROPHAGE TARGET CELLS INFECTED WITH THE MURINE ENCEPHALOMYELITIS VIRUS

  2019cites this paper
• Therapeutic Stem Cells and Their Utilization in Multiple Sclerosis Clinical Trials: A Mini Review

  2019cites this paper
• Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

  2019cites this paper
• Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?

  2018cites this paper
• Etude Multimodale IRM et Electrophysiologique de la Sclérose en Plaques

  2018cites this paper
• Comorbidity in US patients with multiple sclerosis

  2018cites this paper
• Simultaneous Ablation of Neuronal Neurofascin and Ankyrin G in Young and Adult Mice Reveals Age-Dependent Increase in Nodal Stability in Myelinated Axons and Differential Effects on the Lifespan

  2018cites this paper
• Optical coherence tomography as a means to characterize visual pathway involvement in multiple sclerosis

  2018cites this paper
• What's happening in Neurology® Clinical Practice

  2018cites this paper
• Exploring experimental autoimmune optic neuritis using multimodal imaging

  2018cites this paper
• Chapter 6 PET imaging of disease progression and treatment effects in the experimental autoimmune encephalomyelitis rat model

  2018cites this paper
• Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

  2017cites this paper
• Use of Software Analytics of Brain MRI (with & without contrast) As Objective Metric in Neurological Disorders and Degenerative Diseases

  2017cites this paper
• Defective autophagy is associated with neuronal injury in a mouse model of multiple sclerosis.

  2017cites this paper
• [Multiple sclerosis: current immunological aspects].

  2017cites this paper
• Corrigendum to ‘Multiple sclerosis: New insights and trends’

  2017cites this paper
• Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis

  2017cites this paper
• The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis

  2017cites this paper
• Multiple Sclerosis and Treatment: Drug Management and Nutrition with Exercise

  2017cites this paper
• Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.

  2016cites this paper
• Multiple sclerosis is prominent in the Gulf states: Review

  2016cites this paper
• Neurodegeneration and remyelination in multiple sclerosis

  2016cites this paper
• Multiple sclerosis: New insights and trends

  2016cites this paper
• Small molecules with anti-inflammatory properties in clinical development.

  2016cites this paper
• Female sex steroids and glia cells: Impact on multiple sclerosis lesion formation and fine tuning of the local neurodegenerative cellular network.

  2016cites this paper
• Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis.

  2016cites this paper
• Dendritic cells as therapeutic targets in neuroinflammation

  2016cites this paper
• The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.

  2016cites this paper
• Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

  2016cites this paper
• Neuronal expression of the transcription factor serum response factor modulates myelination in a mouse multiple sclerosis model

  2015cites this paper
• Développement d’une protéine à libération prolongée, mise au point du procédé d’encapsulation sans solvant halogéné et optimisation du profil de libération.

  2015influential citation
• Remyelination in multiple sclerosis: realizing a long-standing challenge

  2015cites this paper
• Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis – an observational study

  2015cites this paper
• High doses of biotin in chronic progressive multiple sclerosis: a pilot study.

  2015influential citation
• Compounded Formulations of Dimethyl Fumarate Show Significant Variability in Product Characteristics

  2015cites this paper
• Evaluation de traitement de la sclérose en plaques par analyses morphométriques de données d'imagerie par résonance magnétique

  2015cites this paper
• Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

  2015cites this paper
• Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo

  2015cites this paper
• Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial

  2015cites this paper
• Comparative Neuroregenerative Effects of C-Phycocyanin and IFN-Beta in a Model of Multiple Sclerosis in Mice

  2015cites this paper
• Oligodendrocyte Lineage Cells in Chronic Demyelination of Multiple Sclerosis Optic Nerve

  2014cites this paper
• Current automated 3D cell detection methods are not a suitable replacement for manual stereologic cell counting

  2014cites this paper
• Stem cell transplantation in neurological diseases: improving effectiveness in animal models

  2014cites this paper
• PET imaging in multiple sclerosis

  2014cites this paper
• Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

  2014cites this paper
• Thalamus pathology in multiple sclerosis: from biology to clinical application

  2014cites this paper
• Characterization of the NT2‐derived neuronal and astrocytic cell lines as alternative in vitro models for primary human neurons and astrocytes

  2014cites this paper
• [Immunopathology of multiple sclerosis].

  2014cites this paper
• Remyelinating strategies in multiple sclerosis

  2014cites this paper
• New and emerging immune‐targeted drugs for the treatment of multiple sclerosis

  2014cites this paper
• Nutrient Patterns and Risk of Multiple Sclerosis: A Case-Control Study

  2014cites this paper
• Aktualny model immunopatogenezy stwardnienia rozsianego – nowe możliwości terapeutyczne

  2014cites this paper
• New avenues in PET imaging of multiple sclerosis

  2014cites this paper
• Disease Influence on BBB Transport in Neurodegenerative Disorders

  2014cites this paper
• Isolation and Culture of Human Neurons, Microglia, and Astrocytes

  2014cites this paper
• PET Imaging of Disease Progression and Treatment Effects in the Experimental Autoimmune Encephalomyelitis Rat Model

  2014cites this paper
• New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis

  2013cites this paper
• Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects

  2013cites this paper
• [Assessment of the size of the thalamus as a method for the evaluation of the activity of neurodegenerative process after the treatment with cerebrolisin in young patients with multiple sclerosis].

  2013cites this paper
• Can Vitamin D Suppress Endothelial Cells Apoptosis in Multiple Sclerosis Patients?

  2013cites this paper
• The Benefits and Detriments of Macrophages/Microglia in Models of Multiple Sclerosis

  2013cites this paper
• Multiple Sclerosis and the Blood-Central Nervous System Barrier

  2013cites this paper
• Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis

  2013cites this paper
• Role of Microglia in CNS Autoimmunity

  2013cites this paper
• Caractérisation neuro-immunitaire d'un modèle d'encéphalomyélite auto-immune expérimentale spontanée

  2013cites this paper
• Current and Future Therapies for Multiple Sclerosis

  2013influential citation
• Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine

  2013cites this paper
• Cholesterol homeostasis: a key to prevent or slow down neurodegeneration

  2012influential citation